Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure

X
Trial Profile

A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Pre-RELAX-AHF; RELAX; RELAX-AHF
  • Sponsors Corthera; Novartis Pharma
  • Most Recent Events

    • 03 Aug 2022 Results assessing the role of NLR in predicting cardiovascular outcomes in patients with acute heart failure from BLAST-AHF, Pre-RELAX-AHF & RELAX-AHF, published in the American Journal of Cardiology.
    • 01 Apr 2022 Results of a retrospective patient level analysis from 4 randomized controlled trials (NCT02064868, NCT02007720, NCT01870778, NCT00520806) assessing serelaxin in acute heart failure published in the Circulation: Heart Failure
    • 17 Nov 2020 Results assessing real-world cohort of hemodynamically-proven HFpEF few patients will met criteria for enrollment in major HFpEF clinical trials (TOPCAT, I-PRESERVE, PARAGON-HF, and RELAX), presented at the American Heart Association Scientific Sessions 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top